+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
R

Actively Recruiting

Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival. Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up. During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.

Age: 18Years +All GendersPhase 3
477 locations